| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8220234 | International Journal of Radiation Oncology*Biology*Physics | 2014 | 5 Pages |
Abstract
The combination of preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib was well tolerated. The pathologic complete response rate appears promising and may warrant further investigation.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Prajnan MD, MS, MPH, Cathy MD, Miguel A. MD, George J. MD, MS, John M. MD, Y. Nancy MD, Dipen M. MD, Mark F. MS, Marilyn V. RN, OCN, Scott E. MD, PhD, Christopher R. MD, Imad MD, MS, Marc E. MD, Sunil MD, Christopher H. MD,